Red Light and COVID-19: Does the Evidence Support Early Intervention?

Updated on August 24, 2026 | Estimated reading time: 11 minutes

SARS-CoV-2 viral-load timing is not fixed. Studies in contemporary, highly immune populations have observed peak viral RNA or infectious viral load around days three to four after symptom onset, although timing varies with the variant, prior immunity, sampling method, and individual course. This makes early testing and assessment for proven antiviral treatment time-sensitive, but it does not establish a treatment window for photobiomodulation (PBM).

Can light therapy be used to treat early stages of COVID? Current evidence does not establish red or near-infrared PBM as a COVID treatment. Small human trials have evaluated specific PBM protocols, but their results do not show that PBM clears SARS-CoV-2 or that findings from one device apply to other devices.

What follows reviews the published evidence honestly—what it shows, where it stops short, and which technical and quality details determine whether a study can be interpreted or reproduced. By the end, you will understand the proposed mechanisms, the limitations of current clinical evidence, and the regulatory boundaries that should guide responsible communication.

What the science says: light therapy and early COVID-19

Researchers used calibrated optical measurement equipment to examine PBM and COVID-19 references.

The question of whether light therapy can be used to treat early stages of COVID is best answered by defining "early stages" carefully. SARS-CoV-2 often replicates in the upper respiratory tract during the first symptomatic days, but it is not necessarily confined to the nasal mucosa, and peak timing is variable. A 2024 study in Clinical Infectious Diseases found that viral loads in a highly immune adult population commonly peaked around the fourth day of symptoms, while an earlier longitudinal community study found peak infectious viral load around three days after symptom onset. These findings support prompt testing and clinical assessment; they do not prove that nasal PBM changes viral replication or disease progression.

The mechanism under investigation is photobiomodulation. Red and near-infrared photons may interact with cytochrome c oxidase and other possible photoacceptors, producing context- and dose-dependent changes in mitochondrial signaling, nitric oxide, calcium, ATP, and reactive oxygen species. Cytochrome c oxidase is a leading hypothesis rather than an uncontested universal explanation, and a broad PBM mechanism does not establish an antiviral effect against SARS-CoV-2 . Dompe et al. (2020) reviewed PBM mechanisms and clinical applications generally; that review was not a COVID-19 efficacy trial.

A 2020 editorial in Photobiomodulation, Photomedicine, and Laser Surgery proposed that PBM and antiviral photodynamic therapy deserved investigation during the pandemic. The article was written by Reza Fekrazad, not Michael Hamblin, and it did not provide clinical proof of benefit. It is also important not to merge ordinary PBM with antiviral photodynamic therapy, which uses a matched photosensitizer, light, and oxygen to generate a different photochemical effect. The current evidence landscape can be summarized as follows:

1. PBM can alter inflammatory or metabolic markers in some cell, animal, and condition-specific human studies, but responses depend on the complete protocol.
2. Human COVID-19 PBM trials exist, but they are few and use different devices, anatomical sites, wavelengths, schedules, comparators, and endpoints.
3. Applying light in or near the nose is an anatomical research hypothesis, not evidence that light directly suppresses SARS-CoV-2 in nasal tissue.
4. Existing trials are insufficient for a general COVID-19 treatment recommendation or for extrapolation to untested devices.
5. PBM is not included as a standard COVID-19 antiviral treatment in current CDC or WHO guidance.

This article reviews mechanisms, clinical research, measurement requirements, and regulatory boundaries. It does not recommend PBM for preventing or treating COVID-19, and nothing here replaces testing, clinician-directed care, or evidence-based antiviral treatment.

Biological mechanisms that make early-stage timing relevant

Proposed photobiological regulatory mechanisms in nasal epithelial tissue

Understanding why researchers study timing requires a cautious look at what may happen inside a cell when it receives an appropriate light exposure. The following steps describe proposed PBM signaling, not a proven pathway for treating COVID-19.

Step 1: Light interacts with possible cellular photoacceptors. Red and near-infrared light can penetrate tissue to different degrees depending on wavelength, tissue composition, geometry, and delivered dose. Cytochrome c oxidase is frequently proposed as one photoacceptor, but it should not be presented as the only established target or as becoming predictably "more active" in every cell and protocol.

Step 2: Cellular signaling may change. Some PBM studies report changes in ATP, nitric oxide, calcium, mitochondrial membrane potential, or redox signaling. Reactive oxygen species may briefly increase as a signaling event or decrease in already oxidatively stressed models; therefore, "ATP rises and oxidative stress drops" is not a universal sequence. These laboratory observations do not show that extra cellular energy improves antiviral defense or slows SARS-CoV-2 replication.

Step 3: Inflammatory markers may be modulated. PBM has altered cytokines such as IL-6 or TNF-α in some experimental and condition-specific studies, but the direction and size of the response depend on dose, tissue state, disease model, and sampling time. A biomarker change is not the same as lower symptom severity, reduced hospitalization, faster viral clearance, or prevention of immune dysregulation in people with COVID-19.

Step 4: Evidence from other viruses cannot establish COVID-19 efficacy. A 2001 pilot study by Dougal and Kelly evaluated 1072 nm narrow-band light for herpes labialis and reported a clinical healing outcome. It was not conducted by Sigman, did not study SARS-CoV-2, and did not establish a general mucosal antiviral mechanism. HSV-1 lip lesions and an upper-respiratory coronavirus infection differ in virus biology, tissue, wavelength, protocol, and endpoint.

Nasal delivery: why the site of application matters for COVID

The nasal cavity is a relevant research site because SARS-CoV-2 can replicate in the upper respiratory tract during early infection. However, anatomical relevance alone does not prove that intranasal light reaches infected cells at an effective dose or alters viral load. A 2024 randomized home-use study combined a 633 nm intranasal applicator with an 810 nm applicator over the sternum; because both components were delivered together, the study cannot isolate the nasal component or support a different wavelength, device, or schedule .

Red light is generally absorbed and scattered differently from near-infrared light, but statements such as "650 nm reaches the correct nasal depth" or "850 nm is required for deep tissue" are too categorical. Delivered optical energy depends on peak wavelength, spectral bandwidth, irradiance, exposure time, applicator geometry, contact, tissue optical properties, and measurement position. No wavelength label by itself establishes a clinically effective mucosal dose.

Respiratory inflammation and mitochondrial support

SARS-CoV-2 infection can affect mitochondrial and inflammatory signaling in respiratory cells, which is one reason PBM has been proposed for study. Yet evidence that PBM changes mitochondrial markers in other models cannot be converted into a claim that it restores antiviral signaling or prevents COVID-19 progression. The relevant question is whether a defined device and protocol improves prespecified patient outcomes in a well-controlled human trial—not whether a plausible pathway can be drawn.

The defensible distinction is therefore narrow: PBM has proposed host-tissue mechanisms and preliminary, protocol-specific clinical research. Current evidence does not establish that red or near-infrared light directly inactivates SARS-CoV-2, accelerates viral clearance, prevents severe COVID-19, or provides a general "immune boost."

How nasal light therapy works: device design and practical delivery

Intranasal photobiomodulation (PBM) applicator for research use only

A research intranasal PBM system may include a light emitter, applicator, controller, timer, and power source. Designs vary: some place an emitter near or in a nostril, while others illuminate tissue from a short distance. It is unsafe to assume that any generic light source is suitable for direct mucosal contact. Contact use requires model-specific instructions, electrical and thermal controls, appropriate cleaning procedures, and materials evaluated for the intended contact type and duration.

Technical reporting must go beyond a nominal wavelength or electrical wattage. A scientifically interpretable protocol should identify the exact device, emission mode, peak wavelength and spectral bandwidth, average irradiance at the stated treatment plane, illuminated area, treatment time, radiant exposure, distance or contact geometry, session schedule, output uniformity, measurement instrument, calibration status, and relevant temperature conditions. Electrical input or a label such as "3 W LED" is not optical irradiance.

Practical delivery depends on documenting the following parameters:

1. Optical characterization: Report peak wavelength together with spectral bandwidth and measurement uncertainty; there is no universal rule that a few nanometers of drift automatically changes clinical efficacy.
2. Delivered irradiance and radiant exposure: Irradiance must be measured at the stated treatment plane. Radiant exposure in J/cm² depends on average irradiance and exposure time, not irradiance alone.
3. Geometry, area, and temperature: Contact, distance, angle, illuminated area, uniformity, and thermal rise can change the delivered exposure and safety profile.
4. Protocol identity: Treatment time, session frequency, pulse settings, duty cycle, anatomical site, comparator, and endpoint must be reported before two studies can be compared. A frequency value alone is not a protocol.
5. Safety and intended use: Users should rely on the exact instructions, contraindications, warnings, cleaning requirements, and market authorization for the exact model and intended application.

There is no single "most critical" number. Wavelength, spectral distribution, average irradiance, radiant exposure, geometry, tissue, schedule, safety controls, and clinical context work together; none of them independently establishes COVID-19 efficacy.

What the research actually shows: published evidence reviewed

Neutral comparison of PBM COVID-19 evidence levels and trial limitations

What did the 2020 editorial actually argue?

The frequently cited 2020 editorial was written by Reza Fekrazad. It proposed investigation of PBM and antiviral photodynamic therapy based on prior biological and clinical observations; it did not demonstrate that either approach treats COVID-19. PBM and antiviral photodynamic therapy must also remain separate in the article: the latter ordinarily requires a photosensitizer and a defined photochemical protocol, so evidence from that category cannot support a claim that ordinary red or near-infrared PBM kills a virus.

What category of evidence currently exists, and what does that mean?

The record now includes mechanistic reviews, case reports, small controlled studies, and randomized trials. A 2022 randomized double-blind placebo-controlled pilot studied 620–635 nm PBM in 52 hospitalized patients with mild-to-moderate COVID-19 and focused largely on inflammatory and immune biomarkers . A 2024 home-use randomized trial enrolled 294 participants and tested a combined 633 nm intranasal plus 810 nm chest protocol. It reported faster recovery in a prespecified early-treatment subgroup, but the study was open-label, used self-reported symptoms, had no sham device, and disclosed company funding, supplied devices, and author relationships .

These trials mean that "no peer-reviewed clinical trial exists" is incorrect. They do not, however, establish a class-wide treatment effect. Independent, adequately blinded, sham-controlled, multicenter replication with clinically meaningful endpoints and complete adverse-event reporting is still needed. Publication in a photomedicine journal is not by itself a quality guarantee; readers should evaluate design, population, comparator, attrition, endpoint, statistical uncertainty, funding, conflicts, device identity, and protocol completeness.

What results look like in early-stage respiratory viral contexts

Evidence from herpes labialis should not be treated as the closest proof for early COVID-19. The 1072 nm herpes studies involved a different virus, a visible lip lesion, and different exposure conditions. Their outcomes can support a question for further research, but they cannot demonstrate direct antiviral activity against SARS-CoV-2 or validate intranasal PBM.

The most relevant human evidence is therefore the COVID-19 research itself, and even that evidence remains device- and protocol-specific. At present, PBM should be described as investigational for COVID-19. It should not be marketed as an antiviral, used to justify delaying medical assessment, or presented as interchangeable with approved antivirals or other standard care.

Why device quality determines whether research results translate to home use

Comparison of complete PBM protocol documentation versus an incomplete consumer specification

PBM papers differ substantially in reporting quality. A study can only be interpreted or reproduced when its methods identify the device and the delivered optical exposure with enough detail. Recommended fields include peak wavelength, spectral bandwidth, average irradiance, radiant exposure, illuminated area, distance or contact, emission mode, pulse width and duty cycle when applicable, session schedule, measurement plane, instrument, calibration, uncertainty, and thermal conditions. A product-page value measured at the emitter surface cannot automatically be compared with a study value measured at the tissue plane .

A manufacturing quality management system can support repeatability, traceability, supplier controls, corrective actions, and documented inspections, but it does not demonstrate clinical efficacy. REDDOT holds ISO 13485:2016 certification and MDSAP certification . This information should be verified against the scope and validity period of the current certificates.

These certifications alone do not establish the wavelength, irradiance, safety, suitability for mucosal use, or efficacy against COVID-19 of any individual device. Such claims require model-specific test reports, instructions for use, and regulatory records .

The table below captures the key differences between study-comparable documentation and incomplete consumer claims:

IEC 62471:2006 provides a framework for evaluating photobiological hazards from lamps and lamp systems; it does not establish clinical efficacy or complete medical-device safety . For home-use light-therapy medical electrical equipment, IEC 60601-2-83 may also be relevant alongside general electrical, EMC, software, thermal, usability, risk-management, and—where applicable—biocompatibility requirements. The applicable set depends on the exact design, intended use, market, and regulatory pathway.

How wavelength precision affects outcomes

Wavelength matters because tissue absorption, scattering, and possible photoacceptor interactions vary across the spectrum. However, cytochrome c oxidase should not be reduced to universal broad "peaks" that guarantee a biological response between 630–670 nm or 810–850 nm. Proposed action spectra differ across models, and other photoacceptors or mechanisms may contribute. A 650 nm source and a 680 nm source have different spectra, but wavelength alone cannot predict which will be clinically effective.

Red wavelengths generally have shallower penetration characteristics than some near-infrared wavelengths, yet effective delivery depends on the complete exposure and tissue. There is no universal evidence-based rule that 650 nm is the correct nasal wavelength, that a red/near-infrared 1:1 ratio is optimal, or that one fixed irradiance threshold is suitable for all body sites and outcomes.

When reading a study, record the exact device, peak wavelength and bandwidth, average irradiance, radiant exposure, distance or contact, illuminated area, schedule, measurement method, comparator, and endpoint. Even matching all reported optical values does not guarantee comparable outcomes when the device design, population, disease stage, or protocol differs.

What regulators say: approved uses, investigational claims, and responsible boundaries

COVID-19 guidance

Regulatory status is specific to an exact device, legal manufacturer, jurisdiction, and intended use. FDA establishment registration and device listing do not mean that FDA has approved, cleared, or certified a device. CE marking indicates conformity with applicable European requirements; it is not automatically an authorization to make a COVID-19 treatment claim. ISO 13485 and MDSAP concern quality-management systems rather than disease efficacy.

Health Canada's records illustrate why absolute regulatory statements can be misleading. Its database lists a Class II licence for a specific PBM device, while a separate government page records an Investigational Testing Authorization for a COVID-19 trial. A clinical-trial authorization is not the same as a general marketing authorization, and neither record transfers to another device, wavelength, manufacturer, or protocol. Any article discussing approval must quote the current official intended use for the exact device instead of making a class-wide claim.

Current WHO and CDC COVID-19 guidance does not recommend PBM as an antiviral treatment. Evidence-based outpatient management focuses on testing, risk assessment, symptom care, and—when a patient is eligible—authorized or approved antiviral therapy within the required time window. Describing PBM as "investigational" is therefore appropriate, but that description should be grounded in the absence of a guideline recommendation and the limitations of current trials rather than attributed to a nonexistent WHO PBM classification.

For readers, the practical boundary is clear: do not infer a COVID-19 indication from a wavelength, quality certificate, establishment registration, CE mark, ARTG entry, or another device's study. A device should be used only according to its current instructions and authorized intended use, and experimental use should not delay testing, antiviral eligibility assessment, or urgent medical care.

Can light therapy be used to treat early stages of COVID? Based on current evidence, PBM has been studied in small and device-specific human trials, but it is not established as a general COVID-19 treatment. The scientifically responsible answer is "investigational and unproven outside the exact protocols studied," not a broad yes.

Key Takeaways

Peer-reviewed PBM trials for COVID-19 exist, but their findings are preliminary, protocol-specific, and insufficient to establish that light therapy clears SARS-CoV-2 or treats early-stage COVID-19 across devices. Proven care, including prompt risk assessment and eligible antiviral treatment, should take priority; company registrations, quality systems, and optical specifications do not substitute for disease-specific clinical evidence.

FAQ

How to get rid of COVID early stages?

There is no home method that immediately eliminates SARS-CoV-2. People at higher risk of severe disease should contact a healthcare professional promptly because treatment windows are short: oral nirmatrelvir/ritonavir is generally started within five days of symptom onset, while a three-day course of intravenous remdesivir is generally started within seven days. In the United States, nirmatrelvir/ritonavir is FDA-approved for eligible high-risk adults and remains authorized for certain pediatric patients aged 12 years or older and weighing at least 40 kg. Eligibility, drug interactions, kidney or liver considerations, and alternatives require clinical review. Rest, fluids, symptom management, and current respiratory-virus precautions may also be appropriate. Trouble breathing, persistent chest pain, new confusion, inability to wake, or pale, gray, or blue skin, lips, or nail beds requires urgent medical attention.

Can red light therapy help with viruses?

Red light therapy has not been established as a method for directly inactivating viruses inside the body. PBM may alter host-cell signaling or inflammatory markers under certain experimental conditions, but those observations are not proof of viral clearance, lower infectiousness, or faster recovery. Ordinary PBM should not be confused with ultraviolet germicidal systems or antiviral photodynamic therapy using a photosensitizer; each has different mechanisms, safety requirements, intended uses, and evidence.

Can red light therapy help with sickness?

There is no established general "sickness" indication or universal immune-boosting effect for red light therapy. PBM research is condition-, device-, and protocol-specific, with evidence in some areas of tissue repair, pain, or inflammation that cannot automatically be extended to an infectious illness. Anyone with a diagnosed infection should follow clinician-directed care and should not use PBM as a replacement for proven treatment.

What kills the COVID-19 virus in the body?

The immune system clears infected cells and develops antibody and T-cell responses, while approved or authorized antivirals can inhibit parts of the viral replication process when given to eligible patients early. Clearance and recovery time vary, so a fixed one-to-two-week timeline should not be promised. No light-based therapy has been shown to "kill" SARS-CoV-2 inside the human body, and a change in a mitochondrial or inflammatory marker is not evidence of viral inactivation.

References

• Frediani JK, et al. "Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset." Clinical Infectious Diseases. 2024. https://academic.oup.com/cid/article/78/2/301/7285011
• Hakki S, et al. "Onset and Window of SARS-CoV-2 Infectiousness and Temporal Correlation with Symptom Onset." The Lancet Respiratory Medicine. 2022. https://pubmed.ncbi.nlm.nih.gov/35988572/
• Hamblin MR. "Mechanisms and Applications of the Anti-Inflammatory Effects of Photobiomodulation." 2017. https://pubmed.ncbi.nlm.nih.gov/28748217/
• Quirk BJ, Whelan HT. "Effect of Red-to-Near Infrared Light on the Reaction of Isolated Cytochrome c Oxidase with Cytochrome c." 2016. https://pubmed.ncbi.nlm.nih.gov/27111566/
• Dompe C, et al. "Photobiomodulation—Underlying Mechanism and Clinical Applications." Journal of Clinical Medicine. 2020. https://pubmed.ncbi.nlm.nih.gov/32503238/
• Fekrazad R. "Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management." 2020. https://pubmed.ncbi.nlm.nih.gov/32326830/
• Marashian SM, et al. "Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study." Frontiers in Immunology. 2022. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.929837/full
• Zein R, et al. "Review of Light Parameters and Photobiomodulation Efficacy." Journal of Biomedical Optics. 2018. https://www.spiedigitallibrary.org/journals/journal-of-biomedical-optics/volume-23/issue-12/120901/Review-of-light-parameters-and-photobiomodulation-efficacy–dive-into/10.1117/1.JBO.23.12.120901.full
• World Health Organization. "Therapeutics and COVID-19: Living Guideline." https://www.who.int/publications/i/item/B09540
• Centers for Disease Control and Prevention. "COVID-19 Treatment Clinical Care for Outpatients." https://www.cdc.gov/covid/hcp/clinical-care/outpatient-treatment.html
• U.S. Food and Drug Administration. "Important Reminders about Registration and Listing." https://www.fda.gov/medical-devices/device-registration-and-listing/important-reminders-about-registration-and-listing
• International Electrotechnical Commission. IEC 62471:2006 and IEC 60601-2-83:2019. https://webstore.iec.ch/en/publication/7076 and https://webstore.iec.ch/en/publication/32219